

Company Announcement
ASX: HPC

DATE: 10/07/2025

Final Placement of Shortfall Shares

Hydration solutions company **The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte USA or the Company)** is pleased to advise that it has successfully placed the shortfall to the pro rata entitlement offer (**Rights Issue**), announced on 18 March 2025.

The Company has issued 5,000,000 fully paid ordinary shares (**Shares**) at an issue price of \$0.01 per Share. This takes the final total funds raised under the Rights Issue to \$608,878.53 (before costs)¹.

Section 708A(5)(e) Notice

The Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

1. the Company issued 5,000,000 Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - sections 674 and 674A of the Act; and
3. as at the date of this notice, there is no information that is 'excluded information' within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.

An Appendix 2A in relation to the issue of Shares has been lodged separately.

ENDS

This announcement was authorised for release by the Board of HydraLyte USA.

For further information:

Investors/Media

Henry Jordan

Six Degrees Investor Relations

0431 271 538

henry.jordan@sdir.com.au

¹ Refer to ASX announcements released on 16 April 2025, 30 June 2025 and 8 July 2025.